论文部分内容阅读
美国艾博特与日本制药合资公司研制出了一种诊断胰腺癌等消化系统癌症的新药Span-1。reabies,现已应用于临床。胰腺癌临床症状不明显,即使可用诊断药物发现,但在多数情况下,亦不能手术,治疗已晚。据称,新型诊断药物与以往的诊断药物相比,在可手术治疗的时期内发现的比率高,而且将正常细胞误认癌细胞的担心也大为减少。该诊断药是将人体胰腺癌中获得的细胞株(span—1抗原)作为抗原,并与小鼠的细胞聚合而制成单
The United States Abbot and Japan Pharmaceuticals Joint Venture have developed a new drug Span-1 for diagnosing cancers of the digestive system such as pancreatic cancer. Reabies, is now used clinically. The clinical symptoms of pancreatic cancer are not obvious. Even though diagnostic drugs are available, in most cases, surgery is not available and the treatment is too late. It is said that compared with the previous diagnostic drugs, the new diagnostic drugs have a high rate of detection during the operative period, and the fear of mistakenly identifying cancer cells by normal cells is also greatly reduced. The diagnostic drug is a cell strain obtained from human pancreatic cancer (span-1 antigen) as an antigen and is polymerized with mouse cells to form a single